JP2024502371A - 抗－４－１ｂｂ抗体およびｐｄ－１タンパク質またはその断片を含む二重特異的エピトープ結合タンパク質およびその用途 - Google Patents

抗－４－１ｂｂ抗体およびｐｄ－１タンパク質またはその断片を含む二重特異的エピトープ結合タンパク質およびその用途 Download PDF

Info

Publication number
JP2024502371A
JP2024502371A JP2023541864A JP2023541864A JP2024502371A JP 2024502371 A JP2024502371 A JP 2024502371A JP 2023541864 A JP2023541864 A JP 2023541864A JP 2023541864 A JP2023541864 A JP 2023541864A JP 2024502371 A JP2024502371 A JP 2024502371A
Authority
JP
Japan
Prior art keywords
binding protein
epitope binding
cancer
bispecific
bispecific epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023541864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502371A5 (https=
Inventor
クォン、ビョンエス．
リー、ハンナ
パク、ジンソン
ハン、スンヒ
ソン、ヒョンテ
イム、スンウ
パク、ヒョクジュン
ユ、ウンヘ
パク、スンミン
オー、ヨンジ
Original Assignee
ユーティレックス カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーティレックス カンパニー リミテッド filed Critical ユーティレックス カンパニー リミテッド
Publication of JP2024502371A publication Critical patent/JP2024502371A/ja
Publication of JP2024502371A5 publication Critical patent/JP2024502371A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023541864A 2021-01-11 2022-01-11 抗－４－１ｂｂ抗体およびｐｄ－１タンパク質またはその断片を含む二重特異的エピトープ結合タンパク質およびその用途 Pending JP2024502371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135812P 2021-01-11 2021-01-11
US63/135,812 2021-01-11
PCT/IB2022/000009 WO2022149050A2 (en) 2021-01-11 2022-01-11 Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof

Publications (2)

Publication Number Publication Date
JP2024502371A true JP2024502371A (ja) 2024-01-18
JP2024502371A5 JP2024502371A5 (https=) 2025-01-23

Family

ID=82357225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023541864A Pending JP2024502371A (ja) 2021-01-11 2022-01-11 抗－４－１ｂｂ抗体およびｐｄ－１タンパク質またはその断片を含む二重特異的エピトープ結合タンパク質およびその用途

Country Status (6)

Country Link
US (1) US12331116B2 (https=)
EP (1) EP4274852A4 (https=)
JP (1) JP2024502371A (https=)
KR (2) KR102618718B1 (https=)
CN (1) CN117321079A (https=)
WO (1) WO2022149050A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116615442A (zh) * 2020-09-08 2023-08-18 优特力克斯有限公司 程序性细胞死亡1多肽变体
USD1094401S1 (en) * 2023-02-20 2025-09-23 Sony Interactive Entertainment Inc. Display screen or portion thereof with transitional graphical user interface

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162797A1 (en) * 2016-03-23 2017-09-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
WO2019089753A2 (en) * 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
CN110669137A (zh) * 2019-10-24 2020-01-10 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途
JP2020503245A (ja) * 2017-01-06 2020-01-30 ユーティレックス カンパニー リミテッド 抗ヒト４−１ｂｂ抗体およびその使用
JP2020504622A (ja) * 2017-01-03 2020-02-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗４−１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子
WO2020047328A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
WO2020089644A1 (en) * 2018-10-31 2020-05-07 Autolus Limited Binding domain
WO2020107715A1 (en) * 2018-11-30 2020-06-04 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102178323B1 (ko) * 2013-11-29 2020-11-13 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
US10899840B2 (en) * 2014-02-04 2021-01-26 Pfizer Inc. Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
KR102259232B1 (ko) * 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
HUE068868T2 (hu) * 2015-07-30 2025-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
JP2018537076A (ja) * 2015-10-23 2018-12-20 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． プログラム可能な普遍的細胞受容体およびその使用法
WO2017123548A1 (en) * 2016-01-14 2017-07-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Tumor-specific ifna secretion by car t-cells to reprogram the solid tumor microenvironment
US20210054089A1 (en) * 2018-03-23 2021-02-25 Eli Lilly And Company Anti-cd137 antibodies for combination with anti-pd-1 antibodies
WO2019241758A1 (en) * 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
JP7090204B2 (ja) * 2018-07-19 2022-06-23 イーライ リリー アンド カンパニー 免疫チェックポイントを標的とする二重特異性抗体
JP2021535761A (ja) * 2018-09-14 2021-12-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ｓＰＤ−１バリアント−Ｆｃ融合タンパク質
WO2020068500A1 (en) * 2018-09-26 2020-04-02 Albert Einstein College Of Medicine Mutant variants of pd-1 receptor with selective binding to pd-l1 and uses thereof
WO2020229844A1 (en) * 2019-05-15 2020-11-19 Crescendo Biologics Limited Binding molecules
US20210107969A1 (en) * 2019-07-09 2021-04-15 The Johns Hopkins University Molecules, compositions and methods for treatment of cancer
CN116615442A (zh) * 2020-09-08 2023-08-18 优特力克斯有限公司 程序性细胞死亡1多肽变体

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017162797A1 (en) * 2016-03-23 2017-09-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Fusion proteins of pd-1 and 4-1bb
JP2020504622A (ja) * 2017-01-03 2020-02-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗４−１ｂｂクローン２０ｈ４．９を含む二重特異性抗原結合分子
JP2020503245A (ja) * 2017-01-06 2020-01-30 ユーティレックス カンパニー リミテッド 抗ヒト４−１ｂｂ抗体およびその使用
JP2020522495A (ja) * 2017-05-30 2020-07-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物
WO2019089753A2 (en) * 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
WO2020047328A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising pd-1-based chimeric proteins
WO2020089644A1 (en) * 2018-10-31 2020-05-07 Autolus Limited Binding domain
WO2020107715A1 (en) * 2018-11-30 2020-06-04 Abl Bio Inc. Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
CN110669137A (zh) * 2019-10-24 2020-01-10 北京免疫方舟医药科技有限公司 一种多特异性抗体及其制备方法和用途

Also Published As

Publication number Publication date
WO2022149050A3 (en) 2023-04-20
WO2022149050A2 (en) 2022-07-14
US20220275083A1 (en) 2022-09-01
KR102618718B1 (ko) 2023-12-29
EP4274852A4 (en) 2025-02-26
KR102576861B1 (ko) 2023-09-11
EP4274852A2 (en) 2023-11-15
KR20230031376A (ko) 2023-03-07
KR20220162808A (ko) 2022-12-08
CN117321079A (zh) 2023-12-29
US12331116B2 (en) 2025-06-17

Similar Documents

Publication Publication Date Title
JP7158548B2 (ja) Ｍｕｃ１に特異的に結合する抗体及びその用途
US20220089768A1 (en) Multi-specific protein molecules and uses thereof
RU2745451C1 (ru) Антитела к человеческому интерлейкину-2 и их применение
JP2021524740A (ja) 抗ｍｕｃ１抗体
BR112020009805A2 (pt) antígeno do mesmo que liga especificamente cd47 humano, o anticorpo ou fragmento de ligação a antígeno, sequência de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos para produzir o anticorpo ou fragmento de ligação a antígeno, para tratar um câncer que expressa cd47 num indivíduo e para induzir apoptose de uma célula que expressa cd47, e, anticorpo mascarado
CN110545845A (zh) 抗cd33抗体药剂
KR102576861B1 (ko) 항-4-1bb 항체 및 pd-1 단백질 또는 이의 단편을 포함하는 이중특이적 에피토프 결합 단백질 및 이의 용도
JP2025098135A (ja) Ｐｄ－１ポリペプチド変異体
US20250270323A1 (en) Hhla2 binding agents with novel activity
EP4276112A1 (en) Anti-fgfr3 antibody and use thereof
JP2022513729A (ja) ヒト化及び親和性成熟抗ｃｅａｃａｍ１抗体
US12122845B2 (en) Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
EP3882271A2 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
HK40103619A (zh) 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途
KR20220082776A (ko) 항-tigit 항체 및 이의 용도
EP4479430A1 (en) Novel methods of therapy
CN119816519A (zh) 抗ror1抗体、包含其的双特异性抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260407